Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.70 |
| ▸ | RAF1 | P04049 | 5/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.70 |
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387736 | 1.00 | KDM4E (0.81) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| SCHEMBL224770 | 0.90 | KDM4E (1.00) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| Bromide SCHEMBL31020961 | 0.88 | KDM4E (0.96) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| Imidazole SCHEMBL9109434 | 0.83 | CYP3A4 (0.71) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| SCHEMBL4434902 | 0.82 | MAPK14 (1.00) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| SCHEMBL6423292 | 0.82 | MAPK14 (1.00) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| Phenol SCHEMBL27639361 | 0.81 | MAPT (0.81) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| SCHEMBL17002313 | 0.80 | MAPK14 (1.00) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| SCHEMBL27335379 | 0.80 | IDO1 (0.80) | KDM4ECYP3A4MAPTMAPK14MAPK13 | |
| SCHEMBL10397990 | 0.80 | KDM4E (0.79) | KDM4ECYP3A4MAPTMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102190625-A | Stilbene tumor targeted medicine Combretastatin A4 analogs | NANJING SANHOME PHARMACEUTICAL CO LTD | 2011-09-21 | — | — | CN | claimed |
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | Poolbeg Pharma (UK) Limited (GB) | 2025-01-09 | — | — | US | disclosed |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | disclosed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | disclosed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| EP-3478322-B1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| EP-3478322-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | hVIVO Services Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| EP-2843049-B1 | NEURONAL DIFFERENTIATION PROMOTER | UNIV KEIO (JP) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018007788-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LIMITED (GB) | 2018-01-11 | — | — | WO | disclosed |
| US-20150104870-A1 | NEURONAL DIFFERENTIATION PROMOTER | RIKEN (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2843049-A1 | NEURONAL DIFFERENTIATION PROMOTER | Keio University (JP) | 2015-03-04 | — | — | EP | disclosed |
| CN-102190625-B | Stilbene tumor targeted medicine Combretastatin A4 analogs | NANJING SANHOME PHARMACEUTICAL CO LTD | 2013-08-28 | — | — | CN | disclosed |
| CN-102190625-A | Stilbene tumor targeted medicine Combretastatin A4 analogs | NANJING SANHOME PHARMACEUTICAL CO LTD | 2011-09-21 | — | — | CN | disclosed |
| US-20080193504-A1 | Method to Treat and Prevent Posterior Capsule Opacification | THOMAS JEFFERSON UNIVERSITY | 2008-08-14 | — | — | US | disclosed |
| EP-1893292-A2 | METHOD TO TREAT AND PREVENT POSTERIOR CAPSULE OPACIFICATION | THOMAS JEFFERSON UNIVERSITY (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20080044439-A1 | Compositions and Methods for Preventing and Treating Skin and Hair Conditions | KYTHERA BIOPHARMACEUTICALS, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1740047-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING SKIN AND HAIR CONDITIONS | Kythera Biopharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006128152-A2 | METHOD TO TREAT AND PREVENT POSTERIOR CAPSULE OPACIFICATION | THOMAS JEFFERSON UNIVERSITY (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005091891-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING SKIN AND HAIR CONDITIONS | KYTHERA BIOPHARMACEUTICALS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050203111-A1 | Compositions and methods for preventing and treating skin and hair conditions | VVII NEWCO 2003, INC. (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, MAPK1 | KDM4E 2944/4885CYP3A4 3916/4885MAPT 3752/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | KDM4E 2814/4885CYP3A4 3938/4885MAPT 3797/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | KDM4E 2814/4885CYP3A4 3938/4885MAPT 3797/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | KDM4E 2944/4885CYP3A4 3916/4885MAPT 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.